This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2014 Nov;11(11):599.

doi: 10.1038/nrurol.2014.252. Epub 2014 Sep 9.

Prostate cancer: androgen suppression duration and zoledronic acid: under the RADAR

Lisa Hutchinson

PMID: 25201618
DOI: 10.1038/nrurol.2014.252

Comment

Prostate cancer: androgen suppression duration and zoledronic acid: under the RADAR

Lisa Hutchinson. Nat Rev Urol. 2014 Nov.

. 2014 Nov;11(11):599.

doi: 10.1038/nrurol.2014.252. Epub 2014 Sep 9.

Author

Lisa Hutchinson

PMID: 25201618
DOI: 10.1038/nrurol.2014.252

No abstract available

PubMed Disclaimer

Comment on

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, Atkinson C, Tai KH, Christie D, Kenny L, Turner S, Gogna NK, Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A. Denham JW, et al. Lancet Oncol. 2014 Sep;15(10):1076-89. doi: 10.1016/S1470-2045(14)70328-6. Epub 2014 Aug 14. Lancet Oncol. 2014. PMID: 25130995 Clinical Trial.

References

1. Lancet Oncol. 2014 Sep;15(10):1076-89 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information